poly-ICLC

Oncovir is a clinical-stage biotechnology company based in Washington, D.C., dedicated to the development of Hiltonol (poly-ICLC), a synthetic double-stranded RNA (dsRNA) that serves as a potent Toll-like receptor 3 (TLR3) and MDA5 agonist. Hiltonol is designed to mimic the presence of a viral infection, thereby activating the innate and adaptive immune systems to produce type I interferons and stimulate T-cell responses. The company's primary focus is on oncology, where Hiltonol is evaluated as a vaccine adjuvant and a standalone immunotherapy in combination with other agents like checkpoint inhibitors and dendritic cell vaccines. Oncovir's pipeline includes numerous clinical trials for indications such as glioblastoma, melanoma, and various solid tumors, as well as infectious diseases like HIV and COVID-19.